Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
Miguel, a 63-year-old Los Angeles teacher, recently marked the 38th anniversary of his diagnosis with HIV. The doctor had told him he would be dead in a couple of years. He lived fearful that each ...
News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Anemia is a common complication of HIV. There are numerous possible causes, including HIV itself, related infections, and some HIV medications. Taking certain medications and adjusting nutrition may ...
Activities staff member Robert Hardrick teaches chair tai chi for residents of Broadway House for Continuing Care in New Jersey. (Photo: Courtesy of Broadway House) Nursing home patients with HIV may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback